Allspring Global Investments
SAGE

Allspring Global Investments’s Sage Therapeutics SAGE Stock Holding History

Allspring Global Investments’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-198
Closed -$1.43K – 2298
2024
Q3 		$1.43K Sell
198
-48,610
-100% -$445K ﹤0.01% 2297
2024
Q2 		$530K Buy
48,808
+176
+0.4% +$2.25K ﹤0.01% 1497
2024
Q1 		$911K Sell
48,632
-6,956
-13% -$160K ﹤0.01% 1393
2023
Q4 		$1.2M Sell
55,588
-3,205
-5% -$63.5K ﹤0.01% 1295
2023
Q3 		$1.21M Sell
58,793
-43,850
-43% -$1.27M ﹤0.01% 1318
2023
Q2 		$4.83M Buy
102,643
+8,200
+9% +$408K 0.01% 1013
2023
Q1 		$3.96M Buy
94,443
+6,871
+8% +$295K 0.01% 1056
2022
Q4 		$3.34M Sell
87,572
-9,961
-10% -$380K 0.01% 1099
2022
Q3 		$3.82M Buy
97,533
+24,367
+33% +$942K 0.01% 1049
2022
Q2 		$2.36M Sell
73,166
-1,260
-2% -$42.2K ﹤0.01% 1175
2022
Q1 		$2.46M Sell
74,426
-1,811
-2% -$68.1K ﹤0.01% 1401
2021
Q4 		$3.24M Buy
+76,237
New +$3.19M ﹤0.01% 1328

Other funds holding SAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Allspring Global Investments's SAGE Position: Q4 2024 in Review

Allspring Global Investments sold out of Sage Therapeutics (SAGE) in Q4 2024, closing a stake of 198 shares — an estimated $1.43K sold.

Allspring Global Investments first reported a position in SAGE in Q4 2021 and held it in 12 quarters. The position peaked at $4.83M in Q2 2023. 176 funds tracked by Wall St. Rank hold SAGE as of Q4 2024.

  • Allspring Global Investments reported no remaining Sage Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Allspring Global Investments sold 198 Sage Therapeutics shares in Q4 2024, an estimated $1.43K.
  • Allspring Global Investments first reported a position in Sage Therapeutics in Q4 2021 and held it in 12 quarters.
  • Allspring Global Investments's Sage Therapeutics position peaked at $4.83M in Q2 2023.
  • 176 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2024.

Based on Allspring Global Investments's 13F filing for Q4 2024, filed 29 Jan 2025.